A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| Prostaglandin F Synthase from human, Recombinant | PGF synthase catalyzes the conversions of 4-androstene-3,17-dione to testosterone, estrone to 17β-estradiol, prostaglandin H2 to PGF2α, and PGD2 to 9α,11β-PGF2. Prostaglandin (PG) F2 is synthesized via three pathways. Applications: Prostaglandin f synthase (pgf synthase) is a member of the aldo-keto reductase superfamily of proteins which catalyze the conversion of aldehydes and ketones to thier corresponding alcohols. prostaglandin f synthase is used in cancer research since it is upregulated in many cancers such as breast and prostate cancer. pgf synthase is also used to study kidney and renal cell carcinoma. Group: Enzymes. Synonyms: prostaglandin-D2 11-reduc. Enzyme Commission Number: EC 1.1.1.188. CAS No. 55976-95-9. Purity: > 90% (SDS-PAGE). PGF synthetase. Mole weight: mol wt ~37 kDa. Storage: -70°C. Source: E. coli. Species: Human. prostaglandin-D2 11-reductase; reductase, 15-hydroxy-11-oxoprostaglandin; PGD2 11-ketoreductase; PGF2α synthetase; prostaglandin 11-ketoreductase; prostaglandin D2-ketoreductase; prostaglandin F synthase; prostaglandin F synthetase; synthetase, prostaglandin F2α; prostaglandin-D2 11-reductase; PGF synthetase; NADPH-dependent prostaglandin D2 11-keto reductase; prostaglandin 11-keto reductase; prostaglandin-F synthase; EC 1.1.1.188; 55976-95-9. Cat No: NATE-0552. |  |
| Prostaglandin H1 | Prostaglandin H1 (PGH1) is a COX metabolite of DGLA and is the precursor to all 1-series PGs and thromboxanes. PGH1 is a suicide inhibitor of platelet thromboxane synthase with Ki value of 28 μM. Alternative Names: PGH1; 9S,11R-epidioxy-15S-hydroxy-13E-prostaenoic acid; 9alpha,11alpha-epidioxy-15(S)-hydroxy-13-trans-prostenoic acid. Grades: ≥95%. CAS No. 52589-22-7. Molecular formula: C20H34O5. Mole weight: 354.5. |  |
| Prostaglandin I2 | Prostaglandin I2 is a prostaglandin used primarily to treat pulmonary arterial hypertension (PAH) by relaxing blood vessels and increasing blood flow to the lungs, thereby reducing the workload on the heart. Alternative Names: (5Z,9α,11α,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; 6(9)-Oxy-11,15-dihydroxyprosta-5,13-dienoic acid; Epopreostenol; Epoprostenol; PGI2; PGX; PGX (prostaglandin); Prostacyclin; Prostaglandin X; U 53217; Vasocyclin. Grades: >95%. CAS No. 35121-78-9. Molecular formula: C20H32O5. Mole weight: 352.47. | |
| Prostaglandin I2, Sodium Salt (PGI2, Prostacyclin) | Potent vasodilatory prostaglandin produced by the endothelium. Induces vasodilation, stimulates cAMP formation. Exhibits cytoprotective and fibrinolytic properties. Group: Biochemicals. Grades: Highly Purified. CAS No. 61849-14-7. Pack Sizes: 1mg. US Biological Life Sciences. |  Worldwide |
| prostaglandin-I synthase | A cytochrome P-450 heme-thiolate enzyme. Converts prostaglandin H2 into prostaglandin I2 (prostacyclin). Group: Enzymes. Synonyms: prostacyclin synthase; prostacycline synthetase; prostagladin I2 synthetase; PGI2 synthase; PGI2 synthetase; (5Z,13E)-(15S)-9α,11α-epidioxy-15-hydroxyprosta-5,13-dienoate 6-isomerase. Enzyme Commission Number: EC 5.3.99.4. CAS No. 65802-86-0. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-5512; prostaglandin-I synthase; EC 5.3.99.4; 65802-86-0; prostacyclin synthase; prostacycline synthetase; prostagladin I2 synthetase; PGI2 synthase; PGI2 synthetase; (5Z,13E)-(15S)-9α,11α-epidioxy-15-hydroxyprosta-5,13-dienoate 6-isomerase. Cat No: EXWM-5512. | |
| Prostaglandin J2 | Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with Kis of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC50 value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD)[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: PGJ2. CAS No. 60203-57-8. Pack Sizes: 500 μg (14.95 mM * 100 μL in Methyl acetate). Product ID: HY-113366. |  |
| prostamide/prostaglandin F2α synthase | The enzyme contains a thioredoxin-type disulfide as a catalytic group. Prostamide H2 and prostaglandin H2 are the best substrates; the latter is converted to prostaglandin F2&alpha. The enzyme also reduces tert-butyl hydroperoxide, cumene hydroperoxide and H2O2, but not prostaglandin D2 or prostaglandin E2. Group: Enzymes. Synonyms: prostamide/PGF synthase; prostamide F synthase; prostamide/prostaglandin F synthase; tPGF synthase. Enzyme Commission Number: EC 1.11.1.20. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0502; prostamide/prostaglandin F2α synthase; EC 1.11.1.20; prostamide/PGF synthase; prostamide F synthase; prostamide/prostaglandin F synthase; tPGF synthase. Cat No: EXWM-0502. | |
| prostamide/prostaglandin F2α synthase | The enzyme contains a thioredoxin-type disulfide as a catalytic group. Prostamide H2 and prostaglandin H2 are the best substrates; the latter is converted to prostaglandin F2α. The enzyme also reduces tert-butyl hydroperoxide, cumene hydroperoxide and H2O2, but not prostaglandin D2 or prostaglandin E2. | |
| Prostate Specific Antigen-1 (153-161) | Prostate Specific Antigen-1 (153-161) is a bioactive peptide of Prostate Specific Antigen-1. Prostate-specific antigen is a protein made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly found in semen, but a small amount is also found in blood. Alternative Names: PSA-1 (153-161). | |
| Prostate Specific Antigen (146-154) | Prostate Specific Antigen (146-154) is a truncated fragment of Prostate Specific Antigen. Prostate-specific antigen is a protein made by cells in the prostate gland (both normal cells and cancer cells). PSA is mostly found in semen, but a small amount is also found in blood. Alternative Names: PSA (146-154); gamma-seminoprotein (146-154); kallikrein-3 (146-154); P-30 antigen (146-154). | |
| Prostate-specific antigen (165-174) | Prostate-specific antigen (165-174) is a peptide corresponding to residues 165-174 of Prostatic acid phosphatase. Prostatic acid phosphatase, an enzyme produced by the prostate, may be found in increased amounts in men who have prostate cancer or other diseases. Alternative Names: PAP (165-174); prostatic specific acid phosphatase (165-174). | |
| Prostate-specific antigen (178-187) | Prostate-specific antigen (178-187) is a peptide corresponding to residues 178-187 of Prostatic acid phosphatase. Prostatic acid phosphatase, an enzyme produced by the prostate, may be found in increased amounts in men who have prostate cancer or other diseases. Alternative Names: PAP (178-187); prostatic specific acid phosphatase (178-187). | |
| Prostate Specific Antigen Substrate | Prostate Specific Antigen Substrate is a highly specific fluorescent peptide substrate can be used for measuring prostate-specific antigen (PSA) enzymatic activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 380225-52-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P5990. | |
| Prostatic acid phosphatase (112-120) | Prostatic acid phosphatase (112-120) is a peptide corresponding to residues 112-120 of Prostatic acid phosphatase. Prostatic acid phosphatase, an enzyme produced by the prostate, may be found in increased amounts in men who have prostate cancer or other diseases. Alternative Names: PAP (112-120); prostatic specific acid phosphatase (112-120). | |
| Prostatic acid phosphatase (18-26) | Prostatic acid phosphatase (18-26) is a peptide corresponding to residues 18-26 of Prostatic acid phosphatase. Prostatic acid phosphatase, an enzyme produced by the prostate, may be found in increased amounts in men who have prostate cancer or other diseases. Alternative Names: PAP (18-26); prostatic specific acid phosphatase (18-26). | |
| Prostatic acid phosphatase (299-307) | Prostatic acid phosphatase (299-307) is a peptide corresponding to residues 299-307 of Prostatic acid phosphatase. Prostatic acid phosphatase, an enzyme produced by the prostate, may be found in increased amounts in men who have prostate cancer or other diseases. Alternative Names: PAP (299-307); prostatic specific acid phosphatase (299-307). | |
| Prostatic acid phosphatase from Human, recombinant | ACPP, also known as prostatic acid phosphatase isoform PAP, is a type I integral membrane protein of the plasma membrane and lysosomes, and a secreted form also exists. The concentration of ACPP is elevated in the circulation of prostate cancer patients, making the enzyme a marker for the progression of prostate cancer. Recombinant human ACPP, fused to His-tag at C-terminus, was expressed in insect cell and purified by using conventional chromatography techniques. Group: Enzymes. Synonyms: Prostatic acid phosphatase; PAP; prostatic specific acid phosphatase; PSAP; EC 3.1.3.2; ACP; Acid Phos; 5'-nucleotidase; 5'-NT; Ecto-5'-nucleotidase; Thiamine monophosphatase; TMPase; PAPf39; ACPP; ACP-3, ACP3. Enzyme Commission Number: EC 3.1.3.2. CAS No. 9001-77-8. Purity: > 95% by SDS-PAGE. Apase. Mole weight: 41.8 kDa. Activity: >100,000 units/mg. Storage: Can be stored at 4°C short term (1-2 weeks). For long term storage, aliquot and store at -70°C. Avoid repeated freezing and thawing cycles. Form: Liquid. Source: Baculovirus. Species: Human. Prostatic acid phosphatase; PAP; prostatic specific acid phosphatase; PSAP; EC 3.1.3.2; ACP; Acid Phos; 5'-nucleotidase; 5'-NT; Ecto-5'-nucleotidase; Thiamine monophosphatase; TMPase; PAPf39; ACPP; ACP-3, ACP3. Cat No: NATE-1673. | |
| Prostratin | Prostratin, a natural terpenoid compound, is a PKC activator, with a Ki of 12.5 nM and shows inhibitory effect on HIV-1. Uses: Scientific research. Category: Signaling pathways. CAS No. 60857-08-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-107421. | |
| Prostratin | Prostratin. Group: Biochemicals. Alternative Names: (1aR, 1bS, 4aR, 7aS, 7bR, 8R, 9aS)-9a-(Acetyloxy)-1, 1a, 1b, 4, 4a, 7a, 7b, 8, 9, 9a-decahydro-4a, 7b-dihydroxy-3-(hydroxymethyl)-1, 1, 6, 8-tetramethyl-5H-cyclopropa[3, 4]benz[1, 2-e]azulen-5-one. Grades: Highly Purified. CAS No. 60857-08-1. Pack Sizes: 1mg, 2mg, 5mg, 10mg. Molecular Formula: C22H30O6. US Biological Life Sciences. | Worldwide |
| Prostratin | Prostratin is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). It is an unusual non-tumorigenic phorbol ester and is found in the bark of the mamala tree of Samoa, Homalanthus nutans (Euphorbiaceae). It has potential to be useful in the treatment of HIV as it could flush viral reservoirs in latently infected CD4+ T-cells. It exhibits promising therapeutic potential against other diseases such as cancer and Alzheimer's disease. It inhibits growth and induces differentiation of AML cell lines. It inhibits tumorigenesis in KRAS mutant pancreatic cancer cells and reduces tumor growth in mouse pancreatic tumor models. Uses: Prostratin has potential to be useful in the treatment of hiv. it exhibits promising therapeutic potential against other diseases such as cancer and alzheimer's disease. Alternative Names: 12-Deoxyphorbol-13-acetate; SA 101A; 13-O-Acetylphorbol. Grades: 95%. CAS No. 60857-08-1. Molecular formula: C22H30O6. Mole weight: 390.47. | |
| PROTAC α-synuclein degrader 5 | PROTAC α-synuclein degrader 5 is a highly selective small-molecule degrader (PROTAC) of α-synuclein aggregates, with a DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2781922-42-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-155021. | |
| PROTAC α-Synuclein/Tau degrader 1 | PROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with KDs of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinsons disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3032208-24-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-157839. | |
| PROTAC AR/AR-V7 degrader-1 | PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC50 values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2841308-96-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-162412. | |
| PROTAC AR Degrader-4 | PROTAC AR Degrader-4 comprises a cIAP1 ligand binding group, a linker and an androgen receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs). Alternative Names: (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl (14S,17S,18R)-18-amino-17-hydroxy-14-isobutyl-13,16-dioxo-19-phenyl-3,6,9-trioxa-12,15-diazanonadecanoate; Androstan-3-one, 17-[[(14S,17S,18R)-18-amino-17-hydroxy-14-(2-methylpropyl)-1,13,16-trioxo-19-phenyl-3,6,9-trioxa-12,15-diazanonadec-1-yl]oxy]-, (5α,17β)-; (5α,17β)-17-[[(14S,17S,18R)-18-Amino-17-hydroxy-14-(2-methylpropyl)-1,13,16-trioxo-19-phenyl-3,6,9-trioxa-12,15-diazanonadec-1-yl]oxy]androstan-3-one. CAS No. 1351169-31-7. Molecular formula: C43H67N3O9. Mole weight: 770.01. | |
| PROTAC AR Degrader-8 | PROTAC AR Degrader-8 is the PROTAC degrader for androgen receptor (AR) that degrades AR-FL with DC50s of 0.018 μM and 0.14 μM in 22Rv1 cell and LNCaP cell, degrades AR-V7 with DC50 of 0.026 μM in 22Rv1 cell. PROTAC AR Degrader-8 inhibits the proliferation of cancer cell 22Rv1 and LNCaP with IC50 values of 0.038 μM and 1.11 μM. PROTAC AR Degrader-8 arrests cell cycle at G2/M phase, induces apoptosis in 22Rv1 cell. PROTAC AR Degrader-8 exhibits anticancer efficacy in mouse and zebrafish model. PROTAC AR Degrader-8 can be used for the research of prostate cancer, castration-resistant prostate cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3044108-04-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-170329. | |
| PROTAC AR-V7 degrader-1 | PROTAC AR-V7 degrader-1 is an orally active and selective AR-V7 PROTAC degrader with a DC50 of 0.32 μM (in 22Rv1 cells). PROTAC AR-V7 degrader-1 can inhibit the proliferation of tumor cells and exhibit anti-tumor activity. PROTAC AR-V7 degrader-1 can be used for the research of cancers such as prostate cancer[1].(Pink: VPC-14228 (HY-117669); Black: linker (HY-W041652); Blue: VHL Ligand (HY-112078)). Uses: Scientific research. Category: Signaling pathways. CAS No. 2767440-24-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145479. | |
| PROTAC ATR degrader-1 | PROTAC ATR degrader-1 (compound ZS-7) is a potent PROTAC degrader of ataxia telangiectasia and Rad3-related (ATR), with DC50 of 0.53 μM. PROTAC ATR degrader-1 plays an importnt role in cancer research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2925916-30-7. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-157764. | |
| PROTAC ATR degrader-2 | PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC50 values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC50 of 29.6 nM against ATR, and its IC50 values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of ATR protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3010273-12-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-161615. | |
| PROTAC AURKA degrader 2 | PROTAC AURKA degrader 2 (compound D) is a potent and selective PROTAC AURKA degrader with an IC50 of 3.58 nM. PROTAC AURKA degrader 2 exhibits 21.6-fold selectivity for AURKA over AURKB (IC50 = 77.2 nM). PROTAC AURKA degrader 2 specifically depletes AURKA on the mitotic spindle[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3093582-13-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-180132. | |
| PROTAC Bcl2 degrader-1 | PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1[1] (Blue: CRBN ligand, Black: linker?Pink: Mcl-1/Bcl-2 inhibitor, Nap-1). Uses: Scientific research. Category: Signaling pathways. CAS No. 2378801-85-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-125876. | |
| PROTAC BCL6 Degrader-3 | PROTAC BCL6 Degrader-3 (compound 92) is a BCL6 PROTAC degrader. PROTAC BCL6 Degrader-3 can be used for the study of cancer or an autoimmune disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3005272-58-9. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-186067. | |
| PROTAC Bcl-xL degrader-3 | It is a potent BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Alternative Names: 753b; (2S,4R)-1-((S)-2-(8-(4-(((R)-4'-chloro-4-methyl-6-((4-(4-(((4-(((R)-4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)carbamoyl)phenyl)piperazin-1-yl)methyl)-2,3,4,5-tetrahydro-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)-8-oxooctanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. CAS No. 2471970-60-0. Molecular formula: C82H105ClF3N11O11S4. Mole weight: 1641.49. | |
| PROTAC BCR-ABL Degrader-1 | PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces Bcr-Abl degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3079412-59-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153415. | |
| PROTAC BET-binding moiety 1 | PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2093387-77-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg. Product ID: HY-107451. | |
| PROTAC BET Degrader-1 | PROTAC BET Degrader-1 is a PROTAC connected by ligands for Cereblon and BET, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration. Uses: Scientific research. Category: Signaling pathways. CAS No. 2093386-22-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103633. | |
| PROTAC B-Raf degrader 1 | PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2364367-27-9. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-111758. | |
| PROTAC BRAF-V600E degrader-1 | PROTAC BRAF-V600E degrader-1 (compound 23) is a potent PROTAC BRAF-V600E degrader whlie no degradation activity against BRAF-WT. PROTAC BRAF-V600E degrader-1 exhibits Kd values of 2.4 nM and 2 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-1 degrades BRAF-V600E via the ubiquitin-proteasome system (UPS) and inhibits the growth of melanoma cells[1]. (In the molecular structure, target protein ligand: BI-882370 (HY-107779), red part; E3 ubiquitin enzyme ligand: Pomalidomide (HY-10984), blue part; PROTAC linker: G007-LK (HY-12438), black part. Uses: Scientific research. Category: Signaling pathways. CAS No. 2417296-84-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-137487. | |
| PROTAC BRD4 Degrader-15 | PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 7.2 and 8.1 nM for BRD4 BD1 and BD2, respectively. It effectively degrades the BRD4 protein in PC3 prostate cancer cells. Alternative Names: N-(2-(3-amino-5-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)phenoxy)ethyl)-7-(3,5-difluoropyridin-2-yl)-2-methyl-10-((methylsulfonyl)methyl)-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carboxamide; N-{[2-(3-Amino-5-{2-[({7-(3,5-difluoro-2-pyridinyl)-2-methyl-10-[(methylsulfonyl)methyl]-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulen-9-yl}carbonyl)amino]ethoxy}phenyl)ethoxy]acetyl}-3-methyl-L-valyl-(4R)-4-hydroxy-N-[4-(4-methyl-1,3-thiazol-5-yl)benzyl]-L-prolinamide; L-Prolinamide, N-[2-[2-[3-amino-5-[2-[[[7-(3,5-difluoro-2-pyridinyl)-3,4,6,7-tetrahydro-2-methyl-10-[(methylsulfonyl)methyl]-3-oxo-2H-2,4,7-triazadibenz[cd,f]azulen-9-yl]carbonyl]amino]ethoxy]phenyl]ethoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-. CAS No. 2417370-67-1. Molecular formula: C57H62F2N10O10S2. Mole weight: 1149.29. | |
| PROTAC BRD4 Degrader-2 | PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC50 of 14.2 nM against BRD4 BD1[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2185795-53-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-133136. | |
| PROTAC BRD4 Degrader-5-CO-PEG3-N3 | PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2704602-92-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-133736. | |
| PROTAC BRD9-binding moiety 1 hydrochloride | PROTAC BRD9-binding moiety 1 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC. Uses: Scientific research. Category: Signaling pathways. CAS No. 2448414-41-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107445A. | |
| PROTAC BRD9 Degrader-7 | PROTAC BRD9 Degrader-7 is an orally active, selective BRD9 PROTAC degrader (DC50 = 1.02 nM). PROTAC BRD9 Degrader-7 mediates BRD9 degradation via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-7 exhibits proliferation inhibitory activity in the MV4-11 cells. PROTAC BRD9 Degrader-7 can be used in the research of acute myeloid leukemia and other related malignancies. (Pink: BI 7271: HY-123616, Blue: 5-Aminothalidomide: HY-W023573, Blue + Black: Thalidomide-5-piperazine: HY-W834174, Black: N,N'-Dimethylpiperazine: HY-W539783)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3056013-04-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-155361. | |
| PROTAC BTK Degrader-1 | PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC50 value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth[1]. PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 2801715-13-7. Pack Sizes: 5 mg; 10 mg. Product ID: HY-147943. | |
| PROTAC BTK Degrader-2 | PROTAC BTK Degrader-2 is a potent BTK PROTAC degrader. PROTAC BTK Degrader-2 effectively reduces BTK protein levels[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2250382-66-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-122828. | |
| PROTAC BTK Degrader-6 | PROTAC BTK Degrader-6 (Compound 15) is a PROTAC BTK degrader (DC50: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2767204-39-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-149391. | |
| PROTAC CBP/P300 Degrader-1 | PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2484739-48-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-138536. | |
| PROTAC CDK2/9 Degrader-1 | PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 μM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2408641-24-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-130709. | |
| PROTAC CDK9 Degrader-1 | PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective CDK9 degrader. Uses: Scientific research. Category: Signaling pathways. CAS No. 2118356-96-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103628. | |
| PROTAC CDK9 degrader-2 | PROTAC CDK9 degrader-2 is a potent and selective CDK9 degrader based on PROTAC, with an IC50 of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC. Alternative Names: 1H-1,2,3-Triazole-1-octanamide, 4-[[(5,7-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)oxy]methyl]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-; 8-(4-{[(5,7-Dihydroxy-4-oxo-2-phenyl-4H-chromen-8-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)-N-[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]octanamide; 4-[[(5,7-Dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)oxy]methyl]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-1H-1,2,3-triazole-1-octanamide. Grades: ≥95%. CAS No. 2435721-30-3. Molecular formula: C39H36N6O10. Mole weight: 748.74. | |
| PROTAC CDK9 degrader-9 | PROTAC CDK9 degrader-9 (compound 29) is a highly selective and efficient CDK9 degrader based on PROTAC technology. PROTAC CDK9 degrader-9 can be used in anti-cancer research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3117192-80-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-168518. | |
| PROTAC cGAS degrader-1 | PROTAC cGAS degrader-1 is a potent and selective cGAS PROTAC degrader, with DC50 values of 0.9 μM and 4.6 μM in THP-1 and RAW 264.7 cells, respectively. PROTAC cGAS degrader-1 induces proteasome-mediated degradation of cGAS, inhibits the cGAS signaling pathway, and attenuates double-stranded DNA-induced activation of cGAS in human and mouse cells. PROTAC cGAS degrader-1 is applicable to research related to ulcerative colitis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3118499-89-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-172208. | |
| PROTAC Chk1 degrader-1 | PROTAC Chk1 degrader-1 is a Chk1-targeting PROTAC.PROTAC Chk1 degrader-1 recruits the Cereblon E3 ligase to induce ubiquitination and proteasomal degradation of Chk1.PROTAC Chk1 degrader-1 exhibits Chk1 degradation activity in malignant melanoma cells without showing a hook effect.PROTAC Chk1 degrader-1 can be used for the research of malignant melanoma[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2597167-34-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161108. | |
| PROTAC c-Met degrader-1 | PROTAC c-Met degrader-1 is a selective and orally active c-Met PROTAC degrader with a DC50 of 6.21 nM against c-Met. PROTAC c-Met degrader-1 induces CRBN-dependent ubiquitination and proteasomal degradation of c-Met. PROTAC c-Met degrader-1 induces G0/G1 phase arrest in c-Met-dependent cancer cells. PROTAC c-Met degrader-1 kills c-Met-dependent cancer cells. PROTAC c-Met degrader-1 inhibits tumor growth in animal models. PROTAC c-Met degrader-1 can be used for the research of gastric cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3056647-52-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-168135. | |
| PROTAC DAPK1 Degrader-1 | PROTAC DAPK1 Degrader-1 (Compound CP1) is a DAPK1 PROTAC degrader with a DC50 of 119.6 nM. PROTAC DAPK1 Degrader-1 significantly increased the MDM2 protein level. PROTAC DAPK1 Degrader-1 significantly reduced the levels of cleaved caspase-3 and cleaved PARP in a cell apoptosis model induced by the neurotoxin ceramide, indicating that it effectively inhibits neuronal apoptosis by degrading DAPK1. PROTAC DAPK1 Degrader-1 can be used to study neurological diseases such as cerebral ischemia and traumatic brain injury (pink: DAPK1 ligand (HY-179071); blue: CRBN ligand (HY-10984); black: linker (HY-40171))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3063030-38-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-179055. | |
| PROTAC DDR1 degrader-1 | PROTAC DDR1 degrader-1 is a potent and selective DDR1-targeting PROTAC degrader. PROTAC DDR1 degrader-1 selectively induces full-length DDR1 degradation via the ubiquitin proteasome system, blocking downstream signaling pathways. PROTAC DDR1 degrader-1 inhibits tumor cell migration and invasion. PROTAC DDR1 degrader-1 enhances tumor apoptosis. PROTAC DDR1 degrader-1 exhibits anti-tumor activity in mice. PROTAC DDR1 degrader-1 can be used for the research of DDR1-driven cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3081612-73-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-176184. | |
| PROTAC EED degrader-1 | PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC targeting EED with a pKD of 9.02. PROTAC EED degrader-1 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC50=8.17) targeting the EED subunit[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2639882-72-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-130614. | |
| PROTAC EED degrader-2 | PROTAC EED degrader-2 is a von Hippel-Lindau-based PROTAC targeting EED with a pKD of 9.27. PROTAC EED degrader-2 is a polycomb repressive complex 2 (PRC2) inhibitor (pIC50=8.11) targeting the EED subunit[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2639882-69-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-130615. | |
| PROTAC eEF2K degrader-1 | PROTAC eEF2K degrader-1 (Compound 11l) is an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. PROTAC eEF2K degrader-1 mediates eEF2K degradation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2458170-54-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-146324. | |
| PROTAC EGFR degrader 11 | PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC50 <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a Ki of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC50 <100 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 3034244-71-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-161633. | |
| PROTAC EGFR degrader 2 | PROTAC EGFR degrader 2 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC50 of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM. PROTAC EGFR degrader 2 can be used for the synthesis of nitroreductase (NTR)-responsive PROTAC[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3031336-58-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-144304. | |
| PROTAC EGFR degrader 7 | PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFRL858R/T790M degrader, with a DC50 of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI-H1975 cells proliferation, with an IC50 of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI-H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research[1]. PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 3033297-59-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-147858. | |
| PROTAC EGFR degrader 9 | PROTAC EGFR degrader 9 (Compound C6) is an orally active CRBN-based PROTAC EGFR degrader. PROTAC EGFR degrader 9 exhibits a DC50 of 10.2 nM and a Kd of 240.2 nM against EGFRL858R/T790M/C797S. PROTAC EGFR degrader 9 exhibits potent degradation activity against various EGFR mutants, while sparing the EGFRWT. (Blue: CRBN ligand (HY-A0003), Black: linker (HY-161613); Pink: EGFR inhibitor (HY-161537))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2992670-33-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161536. | |
| PROTAC ERK5 degrader-1 | PROTAC ERK5 degrader-1 (compound 2) is a bifunctional ERK5 PROTAC degrader. PROTAC ERK5 degrader-1 induces ERK5 degradation via VHL-mediated proteasome pathway in MOLT-4 cells. PROTAC ERK5 degrader-1 can be used for the study of a disease or disorder characterized by aberrant ERK5 activity, such as acute lymphoblastic leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2919963-24-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-176528. | |
| PROTAC ERRα Degrader-3 | PROTAC ERRα Degrader-3 is a potent and selective ERRα degrader based on von Hippel-Lindau ligand. PROTAC ERRα Degrader-3 is capable of specifically degrading ERRα protein by >80% at a concentration of 30 nM. PROTAC ERRα Degrader-3 is inactive against ERRβ and ERRγ proteins[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2306388-65-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139185. | |
| PROTAC EZH2 Degrader-1 | PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC50 of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2641601-67-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147525. | |
| PROTAC EZH2 Degrader-2 | PROTAC EZH2 Degrader-2 is a PROTAC EZH2 inhibitor. PROTAC EZH2 Degrader-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner. PROTAC EZH2 Degrader-2 induces apoptosis and reduces mitochondrial membrane potential in SU-DHL-6 cells. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3093642-32-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-157164. | |
| PROTAC FAK degrader 1 | PROTAC FAK degrader 1 (Compound PROTAC-3) is a selective and effective degrader of Fak PROTAC with a DC50 of 3.0 nM. PROTAC FAK degrader 1 reduces the ability of cancer cells to migrate and invade. PROTAC FAK degrader 1 can be used in the study of tumor. (Pink: Fak ligand (HY-44146); Black: Linker (HY-44141); Blue: VHL ligand 1 (HY-125845))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2301916-69-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119932. | |
| PROTAC FKBP Degrader-3 | PROTAC FKBP Degrader-3 is a PROTAC that comprises a FKBP ligand binding group, a linker and an von Hippel-Lindau binding group. PROTAC FKBP Degrader-3 is a potent FKBP degrader[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079056-43-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-135345. | |
| PROTAC FLT-3 degrader 1 | PROTAC FLT-3 degrader 1 is an FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction[1]. IC50: 0.6 nM (FLT-3 ITD). Alternative Names: (2S,4R)-1-[(2S)-2-[3-[2-[2-[2-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]imidazo[2,1-b][1,3]benzothiazol-6-yl]oxyethoxy]ethoxy]propanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide. CAS No. 2230826-81-8. Molecular formula: C52H61N9O9S2. Mole weight: 1020.23. | |
| PROTAC GPX4 degrader-1 | PROTAC GPX4 degrader-1 (DC-2) is a PROTAC-based GPX4 degrader, with a DC50 of 0.03 μM in HT1080 cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2916433-81-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-149236. | |
Our database is helping our users find suppliers everyday.
